drugset / Trial / NCT00853450

Bleeding Time Study With AZD6482, Clopidogrel and ASA

NCT00853450

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.

Timeline

Start
2009-02
Primary completion
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6482 Small molecule Intravenous
Comparator Clopidogrel Small molecule 75 mg Oral
Background ASA Unknown 75 mg Oral

Indications

No indication recorded.